Seeking Alpha

Seeking Alpha Portfolio App for iPad

This Market Current was sent to 13,188 people who get email alerts on ABT.

Get email alerts on ABT »

Market Currents

Abbott Labs (ABT) receives the EU CE's mark for the second generation of its Architect assay,...

Tuesday, August 28, 2012, 9:03 AM ET
Abbott Labs (ABT) receives the EU CE's mark for the second generation of its Architect assay, which measures testosterone levels and has improved sensitivity. (PR)

This Market Current was sent to 13,188 people who get email alerts on ABT.

Get email alerts on ABT »

Share this Market Current

Short URL:

Other date

DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles

Peregrine Pharmaceuticals, The Little Biotech With The Golden Goose Of Immunotherapy
5:49 PM • Chris Lacoursiere
Follow The 'Smart Money' And Buy Johnson & Johnson In The Next Pullback
3:48 PM • Hawkinvest
Why Merck Shares Are Cheap And Could Rise To $60
3:41 PM • Trade In Mexico
Arena Is Still A Great Short
3:08 PM • EnhydrisPECorp
Expanding Use Of Alexion's Specialty Drug Soliris Offers Upside
1:23 PM • Todd Campbell
Arena Buyout More 'Highly Probable' Than MannKind
1:20 PM • Chris_Roberts
Another Look At Marketing Vs. R&D In Pharma
11:29 AM • Derek Lowe
Thoratec, A Bio Stock With Good Potential And Products
8:48 AM • StockRiters
Abbott Laboratories: Undervalued Potential
8:48 AM • Fundamental Analyst
Zalicus Awaiting Data On Potential New Pain Medication
8:19 AM • Len Zehr
MannKind's Afrezza And The Oramed Threat
8:10 AM • Cory Renauer
Johnson & Johnson: At The Crossroads - Part IV - One Road To Higher Profit Growth Rates
6:30 AM • Robert Honeywill
Intuitive Surgical: Years Of Super Growth Ahead
6:30 AM • Fundamental Investor
Will Arena's Belviq Be The Next Anti-Obesity Drug To Make The Cover Of Time Magazine?
2:49 AM • Reasonable Risk
Why Doctors Can Prescribe Arena's Belviq For Off Label Uses Without Worrying About Legal Liability
11:06 PM • Jacob Smith

More Latest Articles »